Research Analysts’ Recent Ratings Updates for BioLife Solutions (BLFS)

BioLife Solutions (NASDAQ: BLFS) recently received a number of ratings updates from brokerages and research firms:

  • 9/24/2020 – BioLife Solutions was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 9/23/2020 – BioLife Solutions had its price target raised by analysts at B. Riley from $25.50 to $30.00.
  • 9/22/2020 – BioLife Solutions had its price target raised by analysts at Northland Securities from $27.00 to $35.00. They now have an “outperform” rating on the stock.
  • 9/22/2020 – BioLife Solutions was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 9/22/2020 – BioLife Solutions had its price target raised by analysts at Lake Street Capital from $29.00 to $35.00. They now have a “buy” rating on the stock.
  • 9/22/2020 – BioLife Solutions had its price target raised by analysts at Maxim Group from $26.00 to $32.00.
  • 9/18/2020 – BioLife Solutions is now covered by analysts at Cowen Inc. They set an “outperform” rating and a $33.00 price target on the stock.
  • 9/15/2020 – BioLife Solutions was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/9/2020 – BioLife Solutions was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “
  • 8/26/2020 – BioLife Solutions was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/19/2020 – BioLife Solutions was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 8/11/2020 – BioLife Solutions was downgraded by analysts at Benchmark Co. from a “buy” rating to a “hold” rating. They now have a $21.00 price target on the stock.
  • 8/8/2020 – BioLife Solutions was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/7/2020 – BioLife Solutions is now covered by analysts at Maxim Group. They set a “buy” rating and a $26.00 price target on the stock.
  • 8/7/2020 – BioLife Solutions had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a $28.00 price target on the stock.
  • 8/3/2020 – BioLife Solutions was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on their proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. “

NASDAQ:BLFS traded up $0.48 during trading hours on Thursday, hitting $29.42. 249,071 shares of the stock traded hands, compared to its average volume of 262,746. BioLife Solutions Inc has a 1 year low of $7.37 and a 1 year high of $29.63. The company has a market cap of $941.50 million, a price-to-earnings ratio of -91.94, a price-to-earnings-growth ratio of 87.50 and a beta of 1.70. The stock has a 50 day moving average price of $22.87 and a 200 day moving average price of $16.80.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported ($0.01) earnings per share for the quarter. BioLife Solutions had a net margin of 42.52% and a return on equity of 1.49%. The firm had revenue of $9.92 million for the quarter, compared to analysts’ expectations of $9.68 million. As a group, research analysts forecast that BioLife Solutions Inc will post 0.03 earnings per share for the current year.

In related news, VP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 15th. The shares were sold at an average price of $19.48, for a total value of $194,800.00. Following the sale, the vice president now owns 202,915 shares in the company, valued at $3,952,784.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Walter Villiger sold 50,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $21.01, for a total transaction of $1,050,500.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 290,466 shares of company stock worth $6,001,709. Company insiders own 22.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in BLFS. Tarsadia Capital LLC bought a new position in BioLife Solutions during the first quarter valued at $4,536,000. Penn Capital Management Co. Inc. purchased a new stake in shares of BioLife Solutions during the first quarter valued at $3,067,000. Russell Investments Group Ltd. boosted its stake in shares of BioLife Solutions by 60.9% during the second quarter. Russell Investments Group Ltd. now owns 674,172 shares of the medical equipment provider’s stock valued at $11,006,000 after purchasing an additional 255,139 shares during the period. Silvercrest Asset Management Group LLC purchased a new stake in shares of BioLife Solutions during the second quarter valued at $3,859,000. Finally, Gagnon Securities LLC purchased a new stake in shares of BioLife Solutions during the second quarter valued at $2,634,000. Institutional investors own 46.90% of the company’s stock.

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: What does a dividend yield signify to investors?

Receive News & Ratings for BioLife Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.